Univ. Bordeaux, CNRS, Bordeaux INP, CBMN, UMR 5248, Institut Européen de Chimie et Biologie, 2 rue Robert Escarpit, F-33607, Pessac, France.
Ureka Pharma SAS, 2 rue Robert Escarpit, F-33607, Pessac, France.
Angew Chem Int Ed Engl. 2021 Feb 1;60(5):2296-2303. doi: 10.1002/anie.202008992. Epub 2020 Dec 1.
Efficient optimization of a peptide lead into a drug candidate frequently needs further transformation to augment properties such as bioavailability. Among the different options, foldamers, which are sequence-based oligomers with precise folded conformation, have emerged as a promising technology. We introduce oligourea foldamers to reduce the peptide character of inhibitors of protein-protein interactions (PPI). However, the precise design of such mimics is currently limited by the lack of structural information on how these foldamers adapt to protein surfaces. We report a collection of X-ray structures of peptide-oligourea hybrids in complex with ubiquitin ligase MDM2 and vitamin D receptor and show how such hybrid oligomers can be designed to bind with high affinity to protein targets. This work should enable the generation of more effective foldamer-based disruptors of PPIs in the context of peptide lead optimization.
高效地将肽类先导化合物优化为候选药物通常需要进一步的改造,以增强其生物利用度等性质。在不同的选择中,折叠体作为具有精确折叠构象的基于序列的寡聚物,已经成为一种很有前途的技术。我们引入寡脲折叠体来降低蛋白-蛋白相互作用(PPI)抑制剂的肽性质。然而,由于缺乏关于这些折叠体如何适应蛋白质表面的结构信息,因此目前对这些类似物的精确设计受到限制。我们报告了一系列与泛素连接酶 MDM2 和维生素 D 受体结合的肽-寡脲杂合体的 X 射线结构,并展示了如何设计这些杂合寡聚物以高亲和力结合蛋白质靶标。这项工作应该能够在肽类先导优化的背景下,生成更有效的基于折叠体的 PPI 破坏剂。